<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518295</url>
  </required_header>
  <id_info>
    <org_study_id>14.33. MET</org_study_id>
    <nct_id>NCT02518295</nct_id>
  </id_info>
  <brief_title>β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion</brief_title>
  <official_title>β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion: Probiotic and Lactose Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess that two β-galactosidase Producing Probiotic Strains
      help improve lactose digestion in subjects with lactose maldigestion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be cross over, randomized in incomplete blocks, controlled, double-blind:

      each subject will be administered 3 products out of 4 (positive control, probiotic
      Streptococcus (S.) thermophilus, probiotic Bifidobacterium (B.) longum, negative control) in
      a random order on 3 different days separated by a washout period of at least one week, and
      maximum 2 weeks between each challenge.

      The total sample size is 42 enrolled subjects/37 completed Patients will be males and females
      aged between 20 and 65 years with positive hydrogen breath test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactose malabsorption as represented by the increase of exhaled hydrogen compared to baseline measured by the hydrogen Breath Test (HBT)</measure>
    <time_frame>HBT measured every hour during 4 hours after challenge (HBT curve)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of improvement of lactose intolerance symptoms using a composite score equal to the sum of individual symptoms measured using a visual analog scale (VAS)</measure>
    <time_frame>4 hours after every milk intake, from the time of ingestion up to 5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Lactose Intolerance</condition>
  <arm_group>
    <arm_group_label>Positive control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultra high temperature (UHT) milk containing 18 g total lactose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control with S. thermophilus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UHT milk containing 18 g total lactose+ S. thermophilus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control with B. longum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UHT milk containing 18 g total lactose+ B. longum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose free milk</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positive control</intervention_name>
    <description>200ml milk containing 18g lactose</description>
    <arm_group_label>Positive control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic S. thermophilus</intervention_name>
    <description>200ml milk containing 18g lactose + probiotic S. thermophilus</description>
    <arm_group_label>Positive control with S. thermophilus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic B. longum</intervention_name>
    <description>200ml milk containing 18g lactose + probiotic B. longum</description>
    <arm_group_label>Positive control with B. longum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Negative control</intervention_name>
    <description>200 ml of UHT Lactose free milk</description>
    <arm_group_label>Negative control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HBT&gt; delta 20ppm (compared with the baseline value) measured at screening visit before
             challenge tests

          2. Having signed the informed consent or having provide his/her legal representative's
             informed consent

        Exclusion Criteria:

          1. Known Food allergy

          2. Any obstructive (COPD, asthma…) or restrictive respiratory syndrome that may impact
             breath test measurements

          3. Any medically relevant malabsorption syndrome

          4. Any medically relevant chronic gut motility disorder other than Irritable Bowel
             Syndrome (IBS), assessed with Rome III questionnaire

          5. Ongoing therapy with drugs known to affect gut motility

          6. Any general antibiotherapy taken during or within 4 weeks of study onset

          7. Use of lactase pill (eg. Lacdigest®), as well as yoghurt and probiotics, for at least
             2 days prior to Visit 0b

          8. Subject who cannot be expected to comply with the study procedures

          9. Currently participating or having participated in another clinical trial during last 8
             weeks prior to the beginning of this study.

         10. To be a close collaborator to the Investigators, either in terms of Family
             relationship and/or professional relationship

         11. Pregnancy, based on anamnesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Duboux</last_name>
    <role>Study Director</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriela Bergonzelli, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic Unit</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

